Ceryvyn Therapeutics Ltd
OPT
Pozycja w akcjach
#31863
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Cena akcji
$0.00846342
Ostatnia synchronizacja: 2026-07-27
Kapitalizacja rynkowa
$11.27M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-99.75%
Kraj
AU
Handel Ceryvyn Therapeutics Ltd (OPT)
Kategoria
Healthcare
Wskaźnik P/S dla Ceryvyn Therapeutics Ltd (OPT)
Wskaźnik P/S na dzień October 2026 TTM: 169.43K
Według najnowszych raportów finansowych i ceny akcji Ceryvyn Therapeutics Ltd, obecny wskaźnik P/S (TTM) wynosi 169.43K. Na koniec 2024 wynosił 1.77K.
Historia wskaźnika P/S dla Ceryvyn Therapeutics Ltd od 2000 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 169.43K | 476.42% |
| 2025 | 29.39K | 1,564.22% |
| 2024 | 1.77K | 65.61% |
| 2023 | 1.07K | -52.90% |
| 2022 | 2.26K | -39.02% |
| 2021 | 3.71K | -11.88% |
| 2020 | 4.21K | 222.41% |
| 2019 | 1.31K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | -100.00% |
| 2008 | 2.87K | -9.31% |
| 2007 | 3.16K | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | 4.11K | -45.80% |
| 2004 | 7.58K | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | -99.99% |
US
|
|
| 40.55 | -99.98% |
US
|
|
| 3.96 | -100.00% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.99% |
NL
|
